CytoDyn initiates Phase 3 Monotherapy Trial for HIV patients
VANCOUVER, Wash.– CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, recently announced that it submitted a Phase 3 protocol for a monotherapy trial, along with the Topline Report for its Phase 2b monotherapy trial to the U.S. Food and Drug Administration (FDA). …